B. Pizzo

发表

Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin

M. Kris, V. Miller, L. Krug, 2004, Clinical Cancer Research.

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

M. Kris, C. Azzoli, J. Ross, 2005, Cancer.

O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma

M. Kris, V. Miller, M. Zakowski, 2003 .

54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial

M. Kris, V. Miller, M. Zakowski, 2003 .

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

M. Kris, C. Azzoli, E. Venkatraman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

William Pao, Valerie Rusch, Christopher Azzoli, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

M. Kris, C. Azzoli, W. Pao, 2007, Cancer.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

M. Kris, W. Pao, L. Ben-Porat, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

M. Kris, V. Miller, L. Krug, 2000, Cancer.

Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).

M. Kris, D. Carbone, A. Sandler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

M. Kris, C. Azzoli, J. Crapanzano, 2005, Cancer.

Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

M. Kris, V. Miller, Douglas B. Johnson, 2000 .

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

M. Kris, D. Carbone, V. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

M. Kris, C. Azzoli, W. Pao, 2005 .

Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.

M. Kris, V. Miller, L. Krug, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

M. Kris, V. Miller, K. Ng, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

M. Kris, P. Hesketh, B. Pizzo, 1997, Journal of the National Cancer Institute.

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.

M. Kris, V. Miller, L. Krug, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.